Enhanced Compositions and Methods for Treating Spinal Muscular Atrophy

The present inventive concept relates to novel compositions and methods for treating spinal muscular atrophy (SMA) by improving the efficacy and delivery of recombinant ALK4:ActRIIB heteromultimers, thereby enhancing treatment outcomes and patient quality of life.

The original patent disclosed compositions and methods for treating SMA using recombinant ALK4:ActRIIB heteromultimers. However, the patent's limitations included potential issues with ligand binding affinity, delivery to motor neurons, and bioavailability. The present inventive concept addresses these limitations by introducing modified heteromultimers with increased ligand binding affinity, conjugation to targeting moieties, controlled release devices, and formulations with permeation enhancers.

The new inventive concept comprises four main aspects. Firstly, the recombinant ALK4:ActRIIB heteromultimer is modified to have increased ligand binding affinity, thereby improving treatment efficacy. Secondly, the heteromultimer is conjugated to a targeting moiety to enhance delivery to motor neurons. Thirdly, a system is designed for controlled release of the heteromultimer over a prolonged period of time. Finally, the heteromultimer is formulated with a permeation enhancer to improve bioavailability. These improvements enable more effective treatment of SMA, leading to better patient outcomes.

The novelty of the present inventive concept lies in the combination of these four aspects, which provide a significant improvement over the original patent. The inventive step resides in the recognition of the limitations of the original patent and the development of innovative solutions to address these limitations, resulting in a more effective and efficient treatment for SMA.

Alternative embodiments of the inventive concept include the use of different targeting moieties, controlled release devices, and permeation enhancers. Additionally, the heteromultimer could be formulated with other therapeutic agents to provide a combination therapy for SMA.

The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of SMA. The improved efficacy and delivery of the recombinant ALK4:ActRIIB heteromultimer could lead to increased adoption and market share in the SMA treatment market.